Form 4: Ligand Pharmaceuticals Director Exercises Stock Options
SEC Form 4 Filing
John W. Kozarich, a director at Ligand Pharmaceuticals, exercised stock options on April 24, 2024, acquiring 2,893 shares of common stock at $39.35 per share.
Summary
- On April 24, 2024, John W. Kozarich, a director of Ligand Pharmaceuticals, exercised non-qualified stock options.
- This transaction involved the acquisition of 2,893 shares of common stock at a price of $39.35 per share.
- Following the transaction, Kozarich directly owns 42,523 shares of Ligand Pharmaceuticals.
- The exercised options were previously granted and fully vested on April 24, 2015, with an original exercise price of $67.53 per share, which was later adjusted due to the OmniAb Inc. separation.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing an insider transaction. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company directors and their holdings in the company's stock.
Stakeholder Impact
- The transaction provides transparency to shareholders regarding the actions of a company director.
Key Dates
| Date | Description |
|---|---|
| 04/24/2015 | Date the options vested in full. |
| 04/24/2024 | Date of the stock option exercise. |
| 04/26/2024 | Date of signature on the Form 4 filing. |
| 06/04/2024 | Expiration date of the Non-Qualified Stock Option. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.